Estimated Wasteful Spending on Aducanumab Dispensing in the U.S. Medicare Population: A Cross-sectional Analysis
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Langa K, Chernew M, Kabeto M, Herzog A, Ofstedal M, Willis R
. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001; 16(11):770-8.
PMC: 1495283.
DOI: 10.1111/j.1525-1497.2001.10123.x.
View
2.
Doraiswamy P, Sperling R, Johnson K, Reiman E, Wong T, Sabbagh M
. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014; 19(9):1044-51.
PMC: 4195975.
DOI: 10.1038/mp.2014.9.
View
3.
Cummings J, Lee G, Zhong K, Fonseca J, Taghva K
. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021; 7(1):e12179.
PMC: 8145448.
DOI: 10.1002/trc2.12179.
View
4.
Mafi J, Leng M, Arbanas J, Tseng C, Damberg C, Sarkisian C
. Estimated Annual Spending on Aducanumab in the US Medicare Program. JAMA Health Forum. 2022; 3(1):e214495.
PMC: 8903103.
DOI: 10.1001/jamahealthforum.2021.4495.
View